KRTL HOLDING GROUP Stock Price, News & Analysis

KRTL Holding Group Inc. (OTC: KRTL) is a diversified holding company that operates through subsidiaries focused on pharmaceuticals, biotechnology, regulatory compliance, active pharmaceutical ingredients (APIs), cosmetics, and consumer health products. According to the company’s public disclosures, KRTL Holding Group Inc. operates primarily through KRTL Biotech Inc. and KRTL International Corp., with additional majority-owned and acquired businesses that expand its reach across international healthcare and wellness markets.

The company’s activities span pharmaceutical manufacturing, regulatory registration, distribution of APIs and finished products, and the development of functional consumer health offerings. Through its subsidiaries and strategic partnerships, KRTL Holding Group Inc. is involved in both pharmaceutical innovation and compliance, aligning manufacturing and distribution with stringent regulatory standards in the United States and abroad.

Subsidiary Structure and Core Operations

KRTL Holding Group Inc. reports that it operates through wholly owned subsidiaries KRTL Biotech Inc. and KRTL International Corp. KRTL Biotech specializes in pharmaceutical registration, regulatory compliance, FDA services, and the development of pharmaceutical products and APIs for international and domestic clients. It plays a central role in product registration and importation, helping products meet U.S. market entry requirements and other international pharmaceutical regulations.

KRTL International Corp. is described as a subsidiary that supports international operations and infrastructure, including joint ventures and projects related to land, facilities, and carbon credit initiatives. Together, these entities support KRTL Holding Group Inc.’s focus on pharmaceutical innovation, regulatory alignment, and cross-border commercialization.

Pharmaceutical Manufacturing and SIGMA Integration

A major component of KRTL Holding Group Inc.’s business is its relationship with Industria Químico Farmacéutica SIGMA Corp. S.R.L. (SIGMA), a Bolivian pharmaceutical manufacturer. The company has announced that its wholly owned subsidiary KRTL Biotech Inc. completed a merger by exchange of quotas and shares with SIGMA, resulting in KRTL Biotech obtaining a majority beneficial interest in SIGMA’s capital quotas. SIGMA’s financial results are consolidated into KRTL Biotech’s statements under U.S. GAAP consolidation guidance.

SIGMA is described as a Bolivian pharmaceutical company with decades of experience in the formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals. KRTL Holding Group Inc. highlights SIGMA’s GMP-certified manufacturing facility in Cochabamba, Bolivia, which produces anti-infective and antibiotic products and supports the manufacture of other pharmaceutical and nutraceutical offerings.

KRTL Holding Group Inc. has also announced the successful registration of SIGMA with the U.S. Food and Drug Administration’s Federal Establishment Identifier (FEI). This registration is presented as a step toward positioning Bolivian-manufactured pharmaceuticals for access to the U.S. market, combining SIGMA’s manufacturing capabilities with KRTL Biotech’s regulatory compliance expertise.

Anti-Infectives, Antibiotics, and Essential Medicines

Through its majority-owned subsidiary KRTL Biotech Inc. and its integration with SIGMA, KRTL Holding Group Inc. reports an expanded portfolio of anti-infective and antibiotic products. These include formulations such as:

• Hostess Suspension (Trimethoprim + Sulfamethoxazole) – described as a broad-spectrum bactericidal product
• Positrin (Erythromycin Ethylsuccinate) – described as a macrolide antibiotic
• Taxonid (Nitazoxanide) – described as a broad-spectrum antiparasitic

The company states that SIGMA’s GMP-certified facility enables production of a broader range of anti-infective therapies, including penicillin derivatives, macrolides, fluoroquinolones, oral suspensions, pediatric antibiotics, and injectables. These offerings are described as aligned with the World Health Organization’s Model List of Essential Medicines, with a focus on serving public health programs and institutional buyers in Bolivia and potentially other markets.

KRTL Holding Group Inc. reports that SIGMA’s anti-infective and antibiotic products contribute to national pharmaceutical distribution in Bolivia, including hospital and public health system supply chains. This operational base supports KRTL Biotech’s confidence in scaling these categories for international demand, subject to applicable regulatory approvals.

Consumer Health and Functional Beverages

In addition to pharmaceuticals, KRTL Holding Group Inc. highlights a consumer health product through KRTL Biotech: ELIXIR, described as a high-performance electrolyte hydration beverage in the Bolivian market. ELIXIR is characterized as a non-alcoholic, hypertonic hydration beverage produced under GMP-compliant conditions at a Bolivian facility associated with KRTL Biotech.

According to the company’s disclosures, ELIXIR is formulated with glucose, sodium, potassium, calcium, magnesium, and citric acid, and is designed to address dehydration associated with physical activity, heat exposure, or alcohol consumption. The product is reported to be available in multiple flavors and packaging formats and is distributed across a large number of retail drugstores, supermarkets, and club stores in Bolivia. KRTL Biotech describes ELIXIR as both a consumer wellness product and a brand with a cultural presence in that market.

API Distribution, Cosmetics, and Nutrivance Global

KRTL Holding Group Inc. has also reported the acquisition by KRTL Biotech Inc. of a majority equity stake in Nutrivance Global, formerly Skidmore Companies LLC. Nutrivance Global is described as an FDA-registered manufacturer specializing in pharmaceutical production, cosmetic development, and advanced formulations. It serves as a contract development and manufacturing organization (CDMO) for KRTL Biotech Inc.

Through this acquisition, KRTL Biotech intends to distribute its portfolio of Active Pharmaceutical Ingredients (APIs) via Nutrivance Global’s established government and private networks. The partnership also includes a data platform that supports real-world decision-making based on real-world data, intended to enhance API deployment and product distribution. The collaboration is described as expanding access to FDA-approved food and beverage products and cosmetic lines for international markets, while maintaining regulatory compliance and supply chain efficiency.

Joint Venture with CIQ and Access to Natural Resources

KRTL Holding Group Inc. has announced a strategic joint venture in Bolivia between its subsidiaries (KRTL Biotech Inc. and KRTL International Corp.) and Centro de Investigaciones Químicas - CIQ S.R.L., a Bolivian research and manufacturing institution. The joint venture includes an interest in land in the Amazon region and is described as supporting sustainable API extraction, advanced research, and manufacturing.

CIQ is characterized as specializing in the extraction and refinement of high-value natural compounds from Bolivia’s ecosystems, including botanical ingredients used in cosmetic and pharmaceutical applications. Through this partnership, KRTL Biotech plans to introduce CIQ’s real estate holdings, cosmetic products, raw materials, minerals, and APIs into the U.S. market via structured regulatory pathways, including alignment with FDA registration requirements and international pharmaceutical regulations.

The joint venture also contemplates development of facilities in Bolivian locations, with KRTL International overseeing infrastructure expansion, carbon credit initiatives, and reforestation projects, while KRTL Biotech manages regulatory compliance for products intended for export.

Neurotechnology and Mental Wellness

KRTL Holding Group Inc. has disclosed the acquisition of Neurogen Brain Balancing, LLC, a neurotechnology company based in the United States. Neurogen is described as providing advanced brain balancing therapies and personalized cognitive optimization systems that use neuromodulation protocols. These applications are reported to include cognitive performance enhancement, stress reduction, and support for post-trauma recovery.

Through this acquisition, Neurogen becomes a subsidiary of KRTL Holding Group Inc., and its operations are being integrated into KRTL’s regulatory and operational infrastructure. The company indicates that this acquisition expands its presence in the mental wellness and neurotechnology space and aligns with its broader focus on biotechnology and global healthcare.

Regulatory Compliance and Corporate Governance

KRTL Holding Group Inc. emphasizes regulatory compliance as a central aspect of its business. KRTL Biotech Inc. is described as specializing in pharmaceutical registration, regulatory compliance, and FDA services, including product registration, importation, and guidance for international and domestic clients. The company reports that it provides strategic regulatory support and navigates complex pharmaceutical compliance and market entry requirements.

In addition, KRTL Holding Group Inc. has announced steps related to SEC Rule 15c2-11 compliance. The company obtained a court order authorizing a structured, court-supervised verification and remediation process of legacy shareholders. This process includes sending notices to shareholders listed in historical records, requesting proof of ownership, and potentially canceling shares tied to non-responsive or unverifiable shareholders through judicial declaration. The company describes this initiative as intended to cleanse shareholder records, strengthen corporate governance, and support efforts toward full Rule 15c2-11 compliance and public market quotation.

Financial Reporting and Trading Venue Ambitions

KRTL Holding Group Inc. has reported financial results for periods including the three and nine months ended September 30, 2025, and has announced the completion of PCAOB-audited consolidated financial statements for prior fiscal years. The company states that these audited financial statements have been uploaded to OTC Markets.

Management has indicated that the acquisition of SIGMA provides a scalable revenue base and that the company intends to evaluate and pursue an uplisting to a more senior marketplace or exchange, subject to applicable listing requirements and market conditions. The company presents this potential uplisting as a way to broaden its investor base and improve trading liquidity, while noting that investors should refer to its filings for comprehensive financial and operational details.

Geographic Focus and International Reach

Based on the company’s disclosures, KRTL Holding Group Inc. is headquartered in Lakewood, Colorado. Its operations and partnerships extend to Bolivia through SIGMA and CIQ, and to other markets via Nutrivance Global and Neurogen Brain Balancing. The company’s strategy includes cross-border pharmaceutical production, export of Bolivian-manufactured products, and regulatory pathways for entry into the United States and other international markets.

Business Model Overview

According to the information provided, KRTL Holding Group Inc.’s business model centers on:

• Owning and operating subsidiaries involved in pharmaceutical manufacturing, APIs, nutraceuticals, cosmetics, and consumer health products.
• Providing regulatory compliance, FDA registration, and market entry services through KRTL Biotech Inc.
• Leveraging partnerships and joint ventures, such as with SIGMA and CIQ, to access manufacturing capacity, natural resources, and research capabilities.
• Expanding into neurotechnology and mental wellness via the acquisition of Neurogen Brain Balancing, LLC.
• Utilizing distribution networks and data platforms through Nutrivance Global to support API and product distribution.

Investors and other stakeholders are encouraged, by the company’s own statements, to review its public filings and press releases for detailed information on financial performance, risks, and strategic initiatives.

FAQs